Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study (BODYGUARD)

LEO Pharma

Status: Completed

Conditions: Psoriasis Vulgaris

Treatments: Drug: Calcipotriol/betamethasone dipropionate gel

Study type: Observational

Funder types: Industry

Identifiers

NCT02636101

NIS-DAIVOBETGEL-1210

Details and patient eligibility

About

This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.

Enrollment: 603 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Psoriasis vulgaris on body
• Patients planned to receive topical treatment on the body with calcipotriol/betamethasone gel
• Written informed consent

Exclusion criteria

• No or very mild symptoms of psoriasis vulgaris on the body at study start
• Any on-going treatments at study start with topical steroids, salicylic acid or its combination
• Other topical treatment for body psoriasis
• Pregnancy or planned pregnancy within treatment period
• Contraindications according to prescribing information.